Organizations Filed Purposes:
THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA.
THE REGENERATIVE RESEARCH FOUNDATION CONTINUES ITS DEDICATION TO ENHANCING THE SCIENTIFIC KNOWLEDGE OF STEM CELLS THROUGH BASIC LABORATORY RESEARCH AND APPLYING THIS KNOWLEDGE TO DEVELOP THERAPIES TO TREAT AND CURE CENTRAL NERVOUS SYSTEM DISEASES INCLUDING SPINAL CORD INJURY, BRAIN DISORDERS, AND RETINAL EYE DISEASE. IN 2019 FOUNDATION INVESTIGATORS PUBLISHED FIVE ARTICLES IN RESPECTED SCIENTIFIC JOURNALS, REPORTING THE RESULTS OF FOUNDATION RESEARCH STUDIES. THESE ARTICLES ARE FREELY AVAILABLE TO BOTH THE SCIENTIFIC AND LAY AUDIENCE THROUGH THE NIH PUB-MED CENTRAL REPOSITORY. THE FOUNDATION SUCCEEDED IN SECURING SEVERAL NEW SOURCES OF FUNDING TO CONTINUE ITS INVESTIGATIONS INTO NEURODEGENERATIVE DISEASES AND DEMENTIA. THIS FUNDING WILL ALLOW THE ORGANIZATION TO EFFECTIVELY PURSUE ITS MISSION AND TO IMPROVE THE HEALTH OF THE GENERAL POPULATION.
THE FOUNDATION CONTINUES TO DEVELOP A TREATMENT FOR AGE-RELATED MACULAR DEGENERATION. AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION IS NEARING COMPLETION AND WILL BE SUBMITTED TO THE FDA IN 2020. THE FOUNDATION ENTERED INTO A PARTNERSHIP AGREEMENT WITH A PRIVATE CORPORATION WHICH WILL PROVIDE FUNDING FOR CLINICAL TRIALS OF THIS PROMISING TREATMENT. THE FOUNDATION OWNS A 50% OWNERSHIP OF THE NEWLY FORMED LUXA BIOTECHNOLOGY, LLC (LUXA), WHICH WAS ESTABLISHED IN AUGUST 2019. LUXA WAS FORMED FOR THE PURPOSE OF DEVELOPING AND COMMERCIALIZING THE FOUNDATION'S RETINAL PIGMENT EPITHELIUM STEM CELL TRANSPLANTATION TECHNOLOGY FOR TREATMENT OF OCULAR DISORDERS INCLUDING MACULAR DEGENERATION IN HUMANS.
FOUNDATION RESEARCHERS CONTINUED THEIR INVESTIGATIONS RELATED TO A POTENTIAL TREATMENT FOR ALZHEIMER'S DISEASE AND OTHER TAU RELATED DEMENTIAS. A PATENT FOR THIS NOVEL TREATMENT WAS FILED DURING FISCAL YEAR 2017. THIS RESEARCH WILL EXPAND THE SCIENTIFIC UNDERSTANDING OF THE DEVELOPMENT AND PROGRESSION OF AD AND OTHER DEMENTIAS AND BENEFIT THE AGING POPULATION.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Sally Temple-Stern Phd | SCIENTIFIC & EXECUTIVE DIRECTOR | 65 | $171,495 |
| Jeffrey H Stern Md Phd | BD MEM/DIR OF TRANSLATIONAL RESEARCH | 20 | $47,400 |
| Amy G Klann Phd Jd | BOARD MEMBER | 1 | $0 |
| Robert Catalano Md | BOARD MEMBER | 1 | $0 |
| Dawn Abbuhl | BOARD MEMBER | 1 | $0 |
| David O Carpenter Md | BOARD MEMBER | 1 | $0 |
| Vito Grasso Mpa Cae | BOARD MEMBER | 1 | $0 |
| John Walsh | BOARD MEMBER | 1 | $0 |
| William Kahn Cpa | CHAIR | 5 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202033189349303188_public.xml